On the public citation graph

Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206

https://doi.org/10.1021/acsinfecdis.9b00217
0 signed · 117 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/phar.1493openalex-snapshot
Adverse Reactions Associated with Systemic Polymyxin Therapy
inferredcites →https://doi.org/10.1016/j.peptides.2017.03.002openalex-snapshot
Structure–activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity
inferredcites →https://doi.org/10.1016/s1473-3099(18)30605-4openalex-snapshot
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
inferredcites →https://doi.org/10.1017/ice.2018.304openalex-snapshot
Re-estimating annual deaths due to multidrug-resistant organism infections
inferredcites →https://doi.org/10.1021/acs.chemrestox.5b00262openalex-snapshot
Investigating Nephrotoxicity of Polymyxin Derivatives by Mapping Renal Distribution Using Mass Spectrometry Imaging
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01593openalex-snapshot
Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
inferredcites →https://doi.org/10.1021/jm400416uopenalex-snapshot
Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections
inferredcites →https://doi.org/10.1021/jm900999hopenalex-snapshot
Structure−Activity Relationships of Polymyxin Antibiotics
inferredcites →https://doi.org/10.1038/ja.2016.146openalex-snapshot
Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections
inferredcites →https://doi.org/10.1039/c7np00023eopenalex-snapshot
Recent advances and perspectives in the design and development of polymyxins
inferredcites →https://doi.org/10.1055/s-0034-1380549openalex-snapshot
Syntheses of Dap-3 Polymyxin Analogues via a Tris-Boc-Protected Polymyxin B Heptapeptide
inferredcites →https://doi.org/10.1074/jbc.m806587200openalex-snapshot
Interactions of Lipopolysaccharide and Polymyxin Studied by NMR Spectroscopy
inferredcites →https://doi.org/10.1093/jac/dkq285openalex-snapshot
The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic
inferredcites →https://doi.org/10.1093/jac/dks536openalex-snapshot
A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies
inferredcites →https://doi.org/10.1093/jac/dkt039openalex-snapshot
Novel derivatives of polymyxins
inferredcites →https://doi.org/10.1093/jac/dku441openalex-snapshot
Imaging the distribution of polymyxins in the kidney
inferredcites →https://doi.org/10.1128/aac.00405-08openalex-snapshot
Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents
inferredcites →https://doi.org/10.1128/aac.01216-15openalex-snapshot
Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes
inferredcites →https://doi.org/10.1128/aac.01333-12openalex-snapshot
Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model
inferredcites →https://doi.org/10.1128/aac.01439-09openalex-snapshot
A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer Membrane
inferredcites →https://doi.org/10.1128/aac.02557-14openalex-snapshot
Uptake of Polymyxin B into Renal Cells
inferredcites →https://doi.org/10.1128/aac.04110-14openalex-snapshot
Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumannii
inferredcites →https://doi.org/10.1246/bcsj.77.1915openalex-snapshot
The Contribution of the N-Terminal Structure of Polymyxin B Peptides to Antimicrobial and Lipopolysaccharide Binding Activity
inferredcites →https://doi.org/10.1246/bcsj.80.543openalex-snapshot
Chemical Conversion of Natural Polymyxin B and Colistin to Their N-Terminal Derivatives
inferredcites →https://doi.org/10.1248/cpb.57.240openalex-snapshot
Contribution of Each Amino Acid Residue in Polymyxin B3 to Antimicrobial and Lipopolysaccharide Binding Activity
inferredcites →https://doi.org/10.1248/cpb.57.332openalex-snapshot
Development of Des-Fatty Acyl-Polymyxin B Decapeptide Analogs with Pseudomonas aeruginosa-Specific Antimicrobial Activity
inferredcites →https://doi.org/10.15620/cdc:82532openalex-snapshot
Antibiotic resistance threats in the United States, 2019
inferredcites →https://doi.org/10.3390/molecules24020249openalex-snapshot
Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics
inferredcites →https://doi.org/10.3390/molecules24030553openalex-snapshot
Structure-Function Studies of Polymyxin B Lipononapeptides
inferredcites →https://doi.org/10.4155/fmc-2016-0091openalex-snapshot
Polymyxins: A New Hope in Combating Gram-Negative Superbugs?

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4636654openalex-extracted
inferred← citeshttps://doi.org/10.1002/0471266949.bmc290openalex-snapshot
Polymyxins as Antibacterials and Antibiotic Potentiators
inferred← citeshttps://doi.org/10.1002/ange.202407764openalex-snapshot
Allenamides as a Powerful Tool to Incorporate Diversity: Thia‐Michael Lipidation of Semisynthetic Peptides and Access to β‐Keto Amides
inferred← citeshttps://doi.org/10.1002/ange.202408360openalex-snapshot
Die Click‐to‐Release‐Aktivierung des Reserveantibiotikums Colistin am Zielort verringert dessen Nierentoxizität
inferred← citeshttps://doi.org/10.1002/anie.202407764openalex-snapshot
Allenamides as a Powerful Tool to Incorporate Diversity: Thia‐Michael Lipidation of Semisynthetic Peptides and Access to β‐Keto Amides
inferred← citeshttps://doi.org/10.1002/anie.202408360openalex-snapshot
A Targeted Click‐to‐Release Activation of the Last‐Resort Antibiotic Colistin Reduces its Renal Cell Toxicity
inferred← citeshttps://doi.org/10.1007/978-3-031-04544-8_1openalex-snapshot
Basic Concepts of Design of Peptide-Based Therapeutics
inferred← citeshttps://doi.org/10.1007/s40265-024-02137-xopenalex-snapshot
Antibacterials with Novel Chemical Scaffolds in Clinical Development
inferred← citeshttps://doi.org/10.1016/b978-0-323-90575-6.00008-9openalex-snapshot
Macrolide, lincosamide, glycopeptide, and other antibacterial antibiotics
inferred← citeshttps://doi.org/10.1016/j.bbamcr.2023.119507openalex-snapshot
Lipopolysaccharide as an antibiotic target
inferred← citeshttps://doi.org/10.1016/j.biotechadv.2024.108371openalex-snapshot
Unearthing naturally-occurring cyclic antibacterial peptides and their structural optimization strategies
inferred← citeshttps://doi.org/10.1016/j.bmcl.2020.127163openalex-snapshot
Direct modifications of the cyclic peptide Polymyxin B leading to analogues with enhanced in vitro antibacterial activity
inferred← citeshttps://doi.org/10.1016/j.bmcl.2021.127799openalex-snapshot
Recent advances in antibacterial agents
inferred← citeshttps://doi.org/10.1016/j.cbpa.2021.102099openalex-snapshot
New potentiators of ineffective antibiotics: Targeting the Gram-negative outer membrane to overcome intrinsic resistance
inferred← citeshttps://doi.org/10.1016/j.copbio.2022.102783openalex-snapshot
Natural products in antibiotic development: is the success story over?
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.116097openalex-snapshot
Studies of antibacterial activity (in vitro and in vivo) and mode of action for des-acyl tridecaptins (DATs)
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116924openalex-snapshot
Design, synthesis, and bioactivity investigation of novel cyclic lipopeptide antibiotics targeting top-priority multidrug-resistant gram-negative bacteria
inferred← citeshttps://doi.org/10.1016/j.ejmech.2026.118575openalex-snapshot
Structure function and design of polymyxins to enable safer and more potent anti Gram negative agents
inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2024.107393openalex-snapshot
Toxicokinetic profiling of VRP-034: Evaluating its potential in mitigating polymyxin-B-associated nephrotoxicity
inferred← citeshttps://doi.org/10.1016/j.medidd.2020.100078openalex-snapshot
Emerging peptide antibiotics with therapeutic potential
inferred← citeshttps://doi.org/10.1016/j.tim.2020.09.008openalex-snapshot
Border Control: Regulating LPS Biogenesis
inferred← citeshttps://doi.org/10.1016/j.trsl.2020.02.008openalex-snapshot
New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae
inferred← citeshttps://doi.org/10.1021/acs.jcim.5c02488openalex-snapshot
Protonation State-dependent Interaction of Polycationic Polymyxins with the Pseudomonas aeruginosa Outer Membrane Using Colistin A as a Model
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01528openalex-snapshot
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00110openalex-snapshot
Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery
inferred← citeshttps://doi.org/10.1021/acsabm.5c00679openalex-snapshot
In Silico Design of Antimicrobial Peptides against Carbapenem-Resistant Acinetobacter baumannii Infections with Enhanced Activity by Nanoformulation
inferred← citeshttps://doi.org/10.1021/acsinfecdis.0c00037openalex-snapshot
Broadening Activity of Polymyxin by Quaternary Ammonium Grafting
inferred← citeshttps://doi.org/10.1021/acsinfecdis.0c00056openalex-snapshot
Design, Synthesis, and Bioactivity of Cyclic Lipopeptide Antibiotics with Varied Polarity, Hydrophobicity, and Positive Charge Distribution
inferred← citeshttps://doi.org/10.1021/acsinfecdis.0c00917openalex-snapshot
Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin
inferred← citeshttps://doi.org/10.1021/acsinfecdis.3c00630openalex-snapshot
Recent Advances in the Development of Polymyxin Antibiotics: 2010–2023
inferred← citeshttps://doi.org/10.1021/acsinfecdis.5c01108openalex-snapshot
Targeting of the Gram-Negative Outer Membrane for Antibiotic Discovery and Potentiation
inferred← citeshttps://doi.org/10.1021/acsinfecdis.6c00742openalex-snapshot
Expanding the Utility of Colistin Adjuvants To Encompass Next-Generation Polymyxins against Polymyxin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae
inferred← citeshttps://doi.org/10.1021/acsmedchemlett.3c00327openalex-snapshot
Lipid Tales: Optimizing Arylomycin Membrane Anchors
inferred← citeshttps://doi.org/10.1021/jacsau.5c00587openalex-snapshot
Structure–Activity Relationship of the Diaminobutyric Acid Residues in Polymyxins
inferred← citeshttps://doi.org/10.1038/s41429-022-00561-3openalex-snapshot
Causes of polymyxin treatment failure and new derivatives to fill the gap
inferred← citeshttps://doi.org/10.1038/s41429-023-00606-1openalex-snapshot
Design, synthesis and antibacterial activity of novel colistin derivatives with thioether bond-mediated cyclic scaffold
inferred← citeshttps://doi.org/10.1038/s41429-025-00822-xopenalex-snapshot
Novel bifunctional antibacterial peptides mediated by a covalent conjugation strategy combat priority multidrug-resistant gram-negative pathogens through dual targets
inferred← citeshttps://doi.org/10.1038/s41467-022-29234-3openalex-snapshot
A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
inferred← citeshttps://doi.org/10.1038/s41467-025-62407-4openalex-snapshot
A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance
inferred← citeshttps://doi.org/10.1038/s41564-023-01369-zopenalex-snapshot
Inhibiting fatty acid synthesis overcomes colistin resistance
inferred← citeshttps://doi.org/10.1038/s41579-020-0340-0openalex-snapshot
Critical analysis of antibacterial agents in clinical development
inferred← citeshttps://doi.org/10.1038/s41579-023-00993-0openalex-snapshot
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
inferred← citeshttps://doi.org/10.1038/s41579-025-01247-xopenalex-snapshot
Bacterial cell envelope-targeting antibiotics
inferred← citeshttps://doi.org/10.1039/d0cs00729copenalex-snapshot
The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions
inferred← citeshttps://doi.org/10.1039/d0cs01026jopenalex-snapshot
Chemically modified and conjugated antimicrobial peptides against superbugs
inferred← citeshttps://doi.org/10.1039/d3md00456bopenalex-snapshot
Semisynthetic polymyxins with potent antibacterial activity and reduced kidney cell toxicity
inferred← citeshttps://doi.org/10.1039/d3pm00014aopenalex-snapshot
Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury in vivo
inferred← citeshttps://doi.org/10.1039/d3sc05124bopenalex-snapshot
Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms
inferred← citeshttps://doi.org/10.1080/1040841x.2024.2369948openalex-snapshot
Current and novel therapies for management of Acinetobacter baumannii -associated pneumonia
inferred← citeshttps://doi.org/10.1080/13543784.2024.2326028openalex-snapshot
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials
inferred← citeshttps://doi.org/10.1080/13543784.2025.2552846openalex-snapshot
Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials
inferred← citeshttps://doi.org/10.1080/14656566.2020.1817386openalex-snapshot
Therapeutic options for difficult-to-treat Acinetobacter baumanniiinfections: a 2020 perspective
inferred← citeshttps://doi.org/10.1080/14787210.2024.2412637openalex-snapshot
Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?
inferred← citeshttps://doi.org/10.1093/jac/dkaa217openalex-snapshot
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli
inferred← citeshttps://doi.org/10.1093/jac/dkae344openalex-snapshot
Advances in the clinical treatment of multidrug-resistant pathogens using polymyxins
inferred← citeshttps://doi.org/10.1101/2023.03.15.532768openalex-snapshot
« In vitro and in vivo combination of lytic phages and octapeptin OPX10053 against β-lactamase-producing clinical isolates of Klebsiella pneumoniae »
inferred← citeshttps://doi.org/10.1124/pharmrev.120.000020openalex-snapshot
Rescuing the Last-Line Polymyxins: Achievements and Challenges
inferred← citeshttps://doi.org/10.1128/aac.00219-24openalex-snapshot
Evaluating nephrotoxicity reduction in a novel polymyxin B formulation: insights from a 3D kidney-on-a-chip model
inferred← citeshttps://doi.org/10.1128/aac.00426-23openalex-snapshot
Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects
inferred← citeshttps://doi.org/10.1128/aac.00505-23openalex-snapshot
Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
inferred← citeshttps://doi.org/10.1128/aac.00712-25openalex-snapshot
Noncytotoxic polymyxin derivatives enhance antibiotic action against multidrug-resistant Gram-negative bacteria
inferred← citeshttps://doi.org/10.1128/aac.00739-21openalex-snapshot
Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206
inferred← citeshttps://doi.org/10.1128/aac.01563-23openalex-snapshot
Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects
inferred← citeshttps://doi.org/10.1128/aac.01738-22openalex-snapshot
In Vivo Pharmacodynamic Profile of EVER206, a Novel Polymyxin Antimicrobial, against Gram-Negative Bacteria in the Murine Thigh Infection Model
inferred← citeshttps://doi.org/10.1128/aac.01940-24openalex-snapshot
The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii
inferred← citeshttps://doi.org/10.1128/jb.00196-23openalex-snapshot
Bacteriophage steering of Burkholderia cenocepacia toward reduced virulence and increased antibiotic sensitivity
inferred← citeshttps://doi.org/10.1128/spectrum.01341-25openalex-snapshot
In vitro activity of SPR206 and comparator agents against Pseudomonas aeruginosa , Acinetobacter species, and Enterobacterales responsible for infection in United States, European, Israeli, and Turkish hospitals
inferred← citeshttps://doi.org/10.1186/s40779-024-00510-1openalex-snapshot
Antimicrobial resistance crisis: could artificial intelligence be the solution?
inferred← citeshttps://doi.org/10.1248/cpb.c19-00842openalex-snapshot
Potent Antibiotics Active against Multidrug-Resistant Gram-Negative Bacteria
inferred← citeshttps://doi.org/10.15252/embr.202256033openalex-snapshot
Fighting antibiotic resistance—strategies and (pre)clinical developments to find new antibacterials
inferred← citeshttps://doi.org/10.1590/0037-8682-0349-2021openalex-snapshot
Overview of polymyxin resistance in Enterobacteriaceae
inferred← citeshttps://doi.org/10.18203/2319-2003.ijbcp20233202openalex-snapshot
Polymyxins leading to nephrotoxicity
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3118078/v1openalex-snapshot
The polymyxin SPR206 remediates gram-negative infections in vivo
inferred← citeshttps://doi.org/10.22038/ijbms.2023.71672.15593openalex-snapshot
Novel drug candidates against antibiotic-resistant microorganisms: A review.
inferred← citeshttps://doi.org/10.3389/fcimb.2022.884365openalex-snapshot
Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens
inferred← citeshttps://doi.org/10.3389/fcimb.2022.909731openalex-snapshot
What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?
inferred← citeshttps://doi.org/10.3389/fmicb.2025.1625300openalex-snapshot
Development of polymyxin- and aminoglycoside-based outer membrane permeabilizers: a review
inferred← citeshttps://doi.org/10.3390/antibiotics11121711openalex-snapshot
Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road
inferred← citeshttps://doi.org/10.3390/antibiotics13010047openalex-snapshot
Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii
inferred← citeshttps://doi.org/10.3390/ijms21176216openalex-snapshot
A Novel Peptide Antibiotic, Pro10-1D, Designed from Insect Defensin Shows Antibacterial and Anti-Inflammatory Activities in Sepsis Models
inferred← citeshttps://doi.org/10.3390/membranes10080181openalex-snapshot
Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance
inferred← citeshttps://doi.org/10.3390/pharmaceutics12111080openalex-snapshot
Bi-Functional Alginate Oligosaccharide–Polymyxin Conjugates for Improved Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
inferred← citeshttps://doi.org/10.3390/pharmaceutics15041310openalex-snapshot
Linker-Free Synthesis of Antimicrobial Peptides Using a Novel Cleavage Reagent: Characterisation of the Molecular and Ionic Composition by nanoESI-HR MS
inferred← citeshttps://doi.org/10.3390/pharmaceutics17010076openalex-snapshot
Nanoformulation of Polymyxin E Through Complex Coacervation: A Pharmacokinetic Analysis
inferred← citeshttps://doi.org/10.4155/fmc-2020-0225openalex-snapshot
Antimicrobial Innovation: a Current Update and Perspective on the Antibiotic Drug Development Pipeline
inferred← citeshttps://doi.org/10.70675/a094d42bz7269z4e11z869az472720a6a615openalex-snapshot
Synthèse et étude d'analogues de sidérophores à large spectre antibactérien
inferred← citeshttps://doi.org/10.70675/fa96ffdazf48az49bdzb343z6056f5564f49openalex-snapshot
Synthesis and study of arylaminoalcools, antimicrobial peptides and their conjugates, with antibacterial properties
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.